# EDGAR Filing Document

**Accession Number:** 0001343009
**File Stem:** 0001683168-26-005078
**Filing Date:** 2026-6
**Character Count:** 60770
**Document Hash:** e55056e6ba19c4e4d8c69ae3c5eb8805
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-26-005078.hdr.sgml**: 20260624

**ACCESSION NUMBER**: 0001683168-26-005078

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 38

**CONFORMED PERIOD OF REPORT**: 20260531

**FILED AS OF DATE**: 20260624

**DATE AS OF CHANGE**: 20260624

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CNBX Pharmaceuticals Inc.
- **CENTRAL INDEX KEY:** 0001343009
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 203373669
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 0831

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-52403
- **FILM NUMBER:** 261113120

**BUSINESS ADDRESS:**
- **STREET 1:** #3 BETHESDA METRO CENTER
- **STREET 2:** SUITE 700
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20814
- **BUSINESS PHONE:** 877-424-2429

**MAIL ADDRESS:**
- **STREET 1:** #3 BETHESDA METRO CENTER
- **STREET 2:** SUITE 700
- **CITY:** BETHESDA
- **STATE:** MD
- **ZIP:** 20814

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cannabics Pharmaceuticals Inc.
- **DATE OF NAME CHANGE:** 20140620

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** American Mining Corp
- **DATE OF NAME CHANGE:** 20110510

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Thrust Energy Corp.
- **DATE OF NAME CHANGE:** 20051031

?xml version='1.0' encoding='ASCII'? CNBX PHARMACEUTICALS INC. 10-Q

[**Table of Contents**](#q3_001)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

_______________

**FORM 10-Q**

_______________

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended May 31, 2026**

**OR**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from ______ to ______.**

**Commission File Number: 000-52403**

**___________________________________________________**

**CNBX PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

___________________________________________________

---

| | |
|:---|:---|
| **Nevada** | **46-5644005** |
| (State or other jurisdiction of<br> incorporation or organization) | (IRS Employer Identification No.) |
| **#3 Bethesda Metro Center, Suite 700**<br> **Bethesda, MD** | **20814** |
| (Address of principal executive offices) | (Zip Code) |

---

**(877) 424-2429**

(Registrant's telephone number, including area code)

**Securities registered under Section 12(b) of the Act:**

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| N/A | N/A |

---

**Securities registered under Section 12(g) of the Act:**

Common Stock, $.0001 Par Value

(Title of class)

**_____________________________________________________**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer", "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act:

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of June 17, 2026, the registrant had 1,605,768,095 shares of its Common Stock, $0.0001 par value, outstanding.

When used in this quarterly report, the terms "CNBX," "the Company," "we," "our," and "us" refer to CNBX Pharmaceuticals Inc. and its wholly-owned subsidiary G.R.I.N Ultra Ltd.

**CNBX PHARMACEUTICALS INC.**

**FORM 10-Q**

**MAY 31, 2026**

**INDEX**

---

| | | |
|:---|:---|:---|
| [Cautionary Note Regarding Forward-Looking Statements](#q3_002) | [Cautionary Note Regarding Forward-Looking Statements](#q3_002) | 3 |
| **[PART I – FINANCIAL INFORMATION](#q3_003)** | **[PART I – FINANCIAL INFORMATION](#q3_003)** | 4 |
| Item 1. | [Consolidated Financial Statements](#q3_004) | 4 |
|  | [Consolidated Balance Sheets as of May 31, 2026 (unaudited) and August 31, 2025](#q3_005) | 4 |
|  | [Consolidated Statements of Operations for the Three and Nine Months Ended May 31, 2026 and May 31, 2025 (unaudited)](#q3_006) | 5 |
|  | [Consolidated Statements of Stockholder's Equity for the Three and Nine Months Ended May 31, 2026 and May 31, 2025 (unaudited)](#q3_007) | 6 |
|  | [Consolidated Statements of Cash Flows for the Nine Months Ended May 31, 2026 and May 31, 2025 (unaudited)](#q3_008) | 8 |
|  | [Notes to Consolidated Financial Statements (unaudited)](#q3_009) | 9 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#q3_010) | 14 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#q3_011) | 17 |
| Item 4. | [Controls and Procedures](#q3_012) | 17 |
| **[PART II – OTHER INFORMATION](#q3_013)** | **[PART II – OTHER INFORMATION](#q3_013)** | 18 |
| Item 1. | [Legal Proceeding](#q3_014) | 18 |
| Item 1A. | [Risk Factors](#q3_015) | 18 |
| Item 2. | [Recent Sale of Unregistered Securities](#q3_016) | 18 |
| Item 5. | [Other Information](#q3_017) | 18 |
| Item 6. | [Exhibits](#q3_018) | 18 |
| **[SIGNATURES](#q3_019)** | **[SIGNATURES](#q3_019)** | 19 |

---

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

Certain information set forth in this Quarterly Report on Form 10-Q, including in Item 2, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere herein may address or relate to future events and expectations and as such constitutes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements which are not historical reflect our current expectations and projections about our future results, performance, liquidity, financial condition, prospects and opportunities and are based upon information currently available to us and our management and their interpretation of what is believed to be significant factors affecting our business, including many assumptions regarding future events. Such forward-looking statements include statements regarding, among other things:

· the size and growth of the potential markets for our products and the ability to serve those markets;

· our expectations regarding our expenses and revenue, the sufficiency of our cash resources and needs for additional financing;

· the rate and degree of market acceptance of any of our products;

· our expectations regarding competition;

· our anticipated growth strategies;

· our ability to attract or retain key personnel;

· our ability to establish and maintain development partnerships;

· regulatory developments in the U.S. and foreign countries, especially those related to change in, and enforcement of, cannabis laws;

· our ability to obtain and maintain intellectual property protection for our products; and

· the anticipated trends and challenges in our business and the market in which we operate.

Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," or "project" or the negative of these words or other variations on these words or comparable terminology. Actual results, performance, liquidity, financial condition and results of operations, prospects and opportunities could differ materially and perhaps substantially from those expressed in, or implied by, these forward-looking statements as a result of various risks, uncertainties and other factors. These statements may be found under the section of our Annual Report on Form 10-K for the year ended August 31, 2025 (filed on December 1<sup>st</sup>, 2025) entitled "Risk Factors" as well as in our other public filings.

In light of these risks and uncertainties, and especially given the start-up nature of our business, there can be no assurance that the forward-looking statements contained herein will in fact occur. Readers should not place undue reliance on any forward-looking statements. Except as expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

**PART I – FINANCIAL INFORMATION**

**Item 1. Financial Statements**

**CNBX PHARMACEUTICALS INC.**

**Consolidated Balance Sheets**

---

| | | |
|:---|:---|:---|
|  | **May 31,**<br>**2026**<br>**Unaudited** | **August 31,**<br>**2025**<br>**Audited** |
| ASSETS |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $9487 | $15111 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other receivables | 3308 | 3326 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 12795 | 18437 |
| Equipment, net | – | – |
| Total assets | $12795 | $18437 |
| LIABILITIES AND STOCKHOLDERS' EQUITY |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | $45228 | $49252 |
| &nbsp;&nbsp;&nbsp;Convertible loan | 1047204 | 1197257 |
| &nbsp;&nbsp;&nbsp;Short term Loan | 120000 |  |
| &nbsp;&nbsp;&nbsp;Due to a related party | 1460077 | 1268221 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 2672509 | 2514730 |
| Stockholders' equity (deficit): |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.0001 par value, 5,000,000 shares authorized, no shares issued and outstanding |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value, 1,800,000,000 shares authorized, 1,475,768,095 and 553,962,206 shares issued and outstanding at May 31, 2026 and August 31, 2025, respectively | 147576 | 55396 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 22773068 | 22716687 |
| &nbsp;&nbsp;&nbsp;Issuance of warrants |  |  |
| &nbsp;&nbsp;&nbsp;Other comprehensive loss |  |  |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (25580358) | (25268376) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity (deficit) | (2659714) | (2496293) |
| Total liabilities and stockholders' equity | $12795 | $18437 |

---

See accompanying notes to consolidated financial statements.

\* On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

**CNBX PHARMACEUTICALS INC.**

**Consolidated Statements of Operations and Comprehensive Loss**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended** | **For the Three Months Ended** | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **May 31,**<br>**2026** | **May 31,**<br>**2025** | **May 31,**<br>**2026** | **May 31,**<br>**2025** |
| Revenues |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Services | $– | $– | $– | $– |
| &nbsp;&nbsp;&nbsp;Cost of services | – | – | – | – |
| &nbsp;&nbsp;&nbsp;Gross Profit | – | – | – | – |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;General and administrative expenses | 162763 | 40380 | 299728 | 141960 |
| Total operating expenses | 162763 | 40380 | 299728 | 141960 |
| Loss from operations | (162763) | (40380) | (299728) | (141960) |
| &nbsp;&nbsp;&nbsp;Other income (loss) |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial income (Loss), net | 8598 | (19347) | (12254) | (21907) |
| Net (loss) | (154165) | (59727) | (311982) | (163867) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total comprehensive income (loss) | $(154165) | $(59727) | $(311982) | $(163867) |
| Net loss per share - basic and diluted: | $(0.00) | $(0.00) | $(0.00) | $(0.00) |
| Weighted average number of shares outstanding - Basic and Diluted | 1318594182 | 42597394 | 995575403 | 35475271 |

---

See accompanying notes to consolidated financial statements.

\* On May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

**CNBX PHARMACEUTICALS INC.**

**Consolidated Statements of Stockholder's Equity**

**(Unaudited)**

**For the nine months ended May 31, 2026**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional Paid In**<br>**Capital** |<br>**Warrants** | **Other Comprehensive**<br>**Gain** | **Accumulated**<br>**Deficit** | **Total**<br> **Stockholders' Equity**<br>**(Deficit)** |
| **Balance, August 31, 2025** | **553962206** | $**55396** | $**22716687** | $– | $– | $**(25268376)** | $**(2496293)** |
| Exercise of a Convertible loan to shares of common stock | 921805889 | 92180 | 56381 |  |  |  | 148561 |
| Net loss | – | – | – | – | – | (311982) | (311982) |
| **Balance, May 31, 2026** | **1475768095** | $**147576** | $**22773068** | $– | $– | $**(25580358)** | $**(2659714)** |

---

**For the three months ended May 31, 2026**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional Paid In**<br>**Capital** |<br>**Warrants** | **Other Comprehensive**<br>**Gain** | **Accumulated**<br>**Deficit** | **Total**<br> **Stockholders' Equity**<br>**(Deficit)** |
| **Balance, February 28, 2026** | **1125768095** | $**112577** | $**22780068** | $– | $– | $**(25426193)** | $**(2533548)** |
| Exercise of a Convertible loan to shares of common stock | 350000000 | 34999 | (7000) |  |  |  | 27999 |
| Net loss | – | – | – | – | – | (154165) | (154165) |
| **Balance, May 31, 2026** | **1475768095** | $**147576** | $**22773068** | $– | $– | $**(25580358)** | $**(2659714)** |

---

**CNBX PHARMACEUTICALS INC.**

**Consolidated Statements of Stockholder's Equity**

**(Unaudited)**

**For the nine months ended May 31, 2025**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional Paid In**<br>**Capital** |<br>**Warrants** | **Other Comprehensive**<br>**Gain** | **Accumulated**<br>**Deficit** | **Total**<br> **Stockholders' Equity**<br>**(Deficit)** |
| **Balance, August 31, 2024** | **31111352** | $**3111** | $**22471309** | $– | $– | $**(24954400)** | $**(2479980)** |
| Exercise of a Convertible loan to shares of common stock | 61400000 | 6140 | 100302 |  |  |  | 106442 |
| Net loss | – | – | – | – | – | (163867) | (163867) |
| **Balance, May 31, 2025** | **92511352** | $**9251** | $**22571611** | $– | $– | $**(25118267)** | $**(2537405)** |

---

**For the three months ended May 31, 2025**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Common Stock** | **Common Stock** | | | | | |
|  | **Shares** | **Amount** | **Additional Paid In**<br>**Capital** |<br>**Warrants** | **Other Comprehensive**<br>**Gain** | **Accumulated**<br>**Deficit** | **Total**<br> **Stockholders' Equity**<br>**(Deficit)** |
| **Balance, February 28, 2025** | **33861352** | $**3386** | $**22484674** | $**–** | $**–** | $**(25058540)** | $**(2570480)** |
| Exercise of a Convertible loan to shares of common stock | 58650000 | 5865 | 86937 |  |  |  | 92802 |
| Net loss | – | – | – | – | – | (59727) | (59727) |
| **Balance, May 31, 2025** | **92511352** | $**9251** | $**22571611** | $– | $– | $**(25118267)** | $**(2537405)** |

---

See accompanying notes to consolidated financial statements.

**CNBX PHARMACEUTICALS INC.**

**Consolidated Statements of Cash Flows**

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended** | **For the Nine Months Ended** |
|  | **May 31,**<br>**2026** | **May 31,**<br>**2025** |
| Cash flows from operating activities: |  |  |
| Net (Loss) | $(311982) | $(163867) |
| Adjustments required to reconcile net loss to net cash used in operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Interest on loans | (1492) | 21479 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts Receivable and pre-paid expenses | 18 |  |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued liabilities | 187832 | (372) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities | (125624) | (142760) |
| Cash flows from financing activities: |  |  |
| &nbsp;&nbsp;&nbsp;Short term loan | 120000 |  |
| &nbsp;&nbsp;&nbsp;Convertible loan | – | 129992 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities | 120000 | 129992 |
| Net increase (Decrease) in cash | (5624) | (12768) |
| Cash and cash equivalents at beginning of the Period | 15111 | 26416 |
| Cash and cash equivalents at end of the Period | $9487 | $13648 |
| Significant non-cash transactions: |  |  |
| &nbsp;&nbsp;&nbsp;Exercise of a Convertible loan to shares of common stock. | $148561 | $106442 |

---

See accompanying notes to consolidated financial statements.

**CNBX PHARMACEUTICALS INC.**

**Notes to Consolidated Financial Statements**

**(Unaudited)**

**Note 1– Nature of Business, Presentation and Going Concern**

***Organization***

CNBX Pharmaceuticals Inc. (the "Company"), was incorporated in the State of Nevada, on September 15, 2004, under the name of Thrust Energy Corp. The Company was originally engaged in the exploration, exploitation, development and production of oil and gas projects within North America, but was unable to operate profitably.

In May 2011, the Company changed its name to American Mining Corporation, suspending its oil and gas operations and changing its business to toll milling and refining, mineral exploration and mine development.

On April 25, 2014, the Company experienced a change in control. Cannabics, Inc. ("Cannabics") acquired a majority of the issued and outstanding common stock of the Company in accordance with stock purchase agreements. On the closing date, April 25, 2014, pursuant to the terms of the Stock Purchase Agreement, Cannabics purchased 41,000,000 shares of the Company's outstanding restricted common stock for $198,000, representing 51%.

On May 21, 2014, the Company changed its name, via merger in the state of Nevada, to CNBX Pharmaceuticals Inc. The Company's principal offices are in Bethesda, Maryland. The Company changed its course of business to laboratory research and development.

On June 19, 2014, FINRA granted final approval of Change of Name & Ticker Symbol of the Corporation from American Mining Corporation to CNBX PHARMACEUTICALS INC., with the new Ticker Symbol of "CNBX". Said approval was predicated upon CNBX Pharmaceuticals Inc.'s filing of Articles of Merger with American Mining Corporation with the Nevada Secretary of State on May 21st, 2014. Under the laws of the State of Nevada, CNBX Pharmaceuticals Inc. was merged with and into the Registrant, with the Registrant being the surviving entity. The Merger was completed under Section 92A.180 of the Nevada Revised Statutes, Chapter 92A, as amended, and as such, does not require the approval of the stockholders of either the Registrant or CNBX Pharmaceuticals Inc.

On August 25, 2014, the Company organized G.R.I.N. Ultra Ltd. ("GRIN"), an Israeli corporation, as a wholly-owned subsidiary. GRIN will provide research and development activities for the Company's products in Israel.

***Stock Split***

On June 3, 2014, the Company's Board of Directors declared a two-to-one forward stock split of all outstanding shares of common stock. The stock split was approved by FINRA on June 25, 2014. The effect of the stock split increased the number of shares of common stock outstanding from 40,880,203 to 81,760,406. All common share and per common share data in these financial statements and related notes hereto have been retroactively adjusted to account for the effect of the stock split for all periods presented prior to June 3, 2014. The total number of authorized common shares and the par value thereof was not changed by the split. Additionally, on May 12, 2022, the Company effected a reverse-split of its common stock on a 1:120 basis.

***Basis of Presentation***

The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial statement presentation and in accordance with Form 10-Q. Accordingly, they do not include all of the information and footnotes required in annual financial statements. In the opinion of management, the unaudited financial statements contain all adjustments (consisting only of normal recurring accruals) necessary to present fairly the financial position and results of operations and cash flows. The results of operations presented are not necessarily indicative of the results to be expected for any other interim period or for the entire year.

These unaudited financial statements should be read in conjunction with our August 31, 2025 annual financial statements included in our Form 10-K, filed with the U.S. Securities and Exchange Commission ("SEC") on December 1<sup>st</sup>, 2025.

***Principles of Consolidation***

The consolidated financial statements include the accounts of the Company and GRIN. All significant inter-company balances and transactions have been eliminated in consolidation.

***Going Concern***

The accompanying unaudited financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. While the Company has incurred a net loss of $311,982 for the nine months ended May 31, 2026, it has incurred cumulative losses since inception of $25,580,358. These conditions raise substantial doubt about the ability of the Company to continue as a going concern.

The ability of the Company to continue as a going concern is dependent upon its abilities to generate revenues, to continue to raise investment capital, and develop and implement its business plan. No assurance can be given that the Company will be successful in these efforts.

***Research and Development Costs***

The Company accounts for research and development costs in accordance with Accounting Standards Codification 730 "Research and Development" ("ASC 730"). ASC 730 requires that research and development costs be charged to expense when incurred. There were no Research and development costs charged to expense for the nine months ended May 31, 2026 and May 31, 2025.

**Note 2 – Related Party Transactions**

As of May 31, 2026, the Company had one employee, our Director Eyal Barad. All employees reside in Israel.

During the nine months ending May 31, 2026, the Company paid $33,487 in salaries, including social benefits as compensation to our CEO and director compared to $37,087 to two directors for the nine months ending May 31, 2025.

In addition, during the nine months ended May 31, 2026 the Company accrued $189,286 in salaries, including socials benefits, to our CEO and chairman, compared to $0 for the nine months ended May 31, 2025.

As of May 31, 2026, the Company had a balance outstanding payable to two directors: Gabriel Yariv and Eyal Barad in the total of $1,213,166.

During the nine months ending May 31, 2026, the Company paid $35,575 as compensation to our CFO compared to $28,036 for the nine months ending May 31, 2025.

As of May 31, 2026, the Company had a balance outstanding payable to CFO in the total of $2,341.

During the nine months ended May 31, 2026 and 2025, the Company has not recorded a non-cash expense in share-based payment, to the company chairman, board members and advisor.

The Company had a balance outstanding on May 31, 2026 and at May 31, 2025 of $223,645 payable to Cannabics, Inc. The advance is due on demand and bears no interest.

**Note 3 – Stockholders' Equity (Deficit)**

***Authorized Shares***

The Company is authorized to issue up to 1,800,000,000 shares of common stock par value $0.0001 per share. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights. The Company's initial Articles authorized 5,000,000 preferred shares at 0.0001 par value, no other attributes have been assigned and no such shares have ever been issued.

***Common Stock***

The Company is authorized to issue up to 1,800,000,000 shares of common stock, par value $0.0001 per share. There is also 5,000,000 shares of Preferred stock, none of which has been issued. Each outstanding share of common stock entitles the holder to one vote per share on all matters submitted to a stockholder vote. All shares of common stock are non-assessable and non-cumulative, with no pre-emptive rights.

During the period ended May 31, 2026, the company issued 921,805,889 shares as a result of conversion of a loan and interest at a total of $148,561.

**Note 4 – Commitments and Contingencies**

We no longer lease any properties.

**Note 5 *–* Private Placement of Notes and Warrant**

On December 16, 2020, we entered into a Securities Purchase Agreement ("SPA") with an institutional investor for a private placement of senior secured convertible notes totaling up to an aggregate of $2,750,000 to be issued in three tranches subject to the achievement of certain milestones. The convertible notes include a conversion right, at the Investor's option, to convert the convertible notes into shares of our Common Stock at a conversion price equal to the lower of (i) $42 per share or (ii) eighty percent (80%) of the average of the two lowest daily volume-weighted average price for the Company's Common Stock during the ten (10) consecutive trading days preceding the conversion date (the "notes"). The investor has the right to have the conversion price reduced if we issue Common Stock or convertible notes at a lower conversion price than $42 during the period that the notes are outstanding. The notes are due one year from issuance. The notes will be interest free, but in the event of a default, they will bear annual interest at a rate of 18.00%. The SPA and the notes contain events of default, including, among other things, failure to repay the notes by the maturity date, and bankruptcy and insolvency events, that would result in the imposition of the default interest rate.

On December 21, 2020, we closed the first tranche and issued a note in the amount of $825,000 (the "Initial Note"). On February 22, 2021, we closed the second tranche and issued a second note in the amount of $550,000 (the "Second Note"). On April 23, 2021, we closed the third tranche and issued a third note in the amount of $1,375,000 (the "Note"). The Initial Note was issued at a discount of $75,000; the Second Note was issued at a discount of $50,000; and the Note was issued at a discount of $125,000. In addition, we issued to the Investor 32,614 shares of Common Stock as pre-delivery shares in accordance with the terms of the SPA, which shares will be deducted from the total number of shares to be issued to the Investor upon conversion of the Initial Note.

On April 23, 2021, we entered into a senior secured promissory note (the "Senior Secured Note") for $1,375,000 with the institutional investor. This follows the SPA, a restated securities purchase agreement dated as of February 22, 2021, as well as accompanying documents for an aggregate principal amount of $2,750,000 having an aggregate original issue discount of 10%, and ranking senior to all outstanding and future indebtedness of the Company. In addition, the SPA granted the investor a right to receive 100% warrant coverage, and we issued a warrant to the investor for up to 45,833 shares of our Common Stock, which expires three years from the issuance date of the warrant, with an exercise price of $60 per share. The warrant may be exercised and converted to Common Stock at the investor's option at any time until the expiration date. These securities were issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Regulation D promulgated thereunder, as these securities were sold to "accredited investors" within the meaning of Regulation D.

On November 28, 2022, we entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through December 12, 2023, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.

On March 16, 2022, we issued to the investor a demand promissory note (the "Demand Note") in the principal amount of $280,000 (the "Principal") with an original issue discount of $40,000. The Demand Note is payable on demand at any time after the earlier to occur of (i) May 16, 2022, and (ii) the public or private offering of any securities by the Company (the "Next Subsequent Placement"). Any amount of Principal due under the Demand Note which is not paid when due shall result in a late charge being incurred and payable by the Company in an amount equal to interest on such amount at the rate of fifteen percent (15%) per annum from the date such amount was due until the same is paid in full (the "Late Charges"). With the agreement, the Principal and accrued and unpaid Late Charges under the Demand Note and amounts owed under the Senior Secured Note may be applied to all, or any part, of the purchase price of securities to be issued upon the consummation of an offering of securities by the Company to the investor. So long as any amounts remain outstanding under the Demand Note or the Senior Secured Note, all cash proceeds received by the Company on or after issuance of the Demand Note from the Next Subsequent Placement or any other sales of any securities of the Company shall be used to (x) first, repay the Demand Note and (y) second, repay the Senior Secured Note.

We entered into a forbearance agreements with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through January 31, 2025, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement.

On June 15, 2022, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $154,250.00. ($154,000 net of issuance expenses). The Convertible Promissory Note carry interest of 9% and due on June 15<sup>th</sup> 2023.

In the period of January through March 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $35,000.00. ($35,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on June 15<sup>th</sup> 2023.

On June 12, 2023, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $65,000.00. ($65,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on August 5<sup>th</sup>, 2023.

On September 24, 2024, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $30,000 ($30,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on January 1, 2025.

On December 30, 2024, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $25,000 ($25,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on April 1, 2025.

On February 3, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $55,000 ($50,000 net of issuance expenses). The Convertible Promissory Note carry interest of 10% and due on October 30, 2025.

On April 24, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $20,000 ($20,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on July 1, 2025.

On June 23, 2025, the Company entered into a Securities Purchase Agreement providing for the issuance of the Convertible Promissory Note in the principal amount of $30,000 ($30,000 net of issuance expenses). The Convertible Promissory Note carry interest of 5% and due on December 31, 2025.

The Institutional Investor agreed to forbear until September 30, 2026 from taking any action against the Company with respect to unpaid amounts owed and to waive certain other defaults under the Note and other rights.

During the period ended May 31, 2026 the Company issued an aggregate of 921,805,889 shares in connection with the conversion of loans and interest in total amount of $148,561.

On December 30, 2025, we entered into a forbearance agreement with the institutional investor relating to that certain Senior Secured Note. Pursuant to the forbearance agreement, the investor, through September 30, 2026, agreed to forbear from exercising any rights and remedies against the Company related to the outstanding payments and to waive certain other defaults under the Senior Secured Note and related rights pursuant to the registration rights agreement entered into in December 2020 between the Company and the investor.

**Note 6 – Segment Reporting**

We operate in a single operating segment and a single reporting segment. Operating segments are defined as components of an enterprise about which separate financial information is regularly evaluated by the chief operating decision maker function (which is fulfilled by our chief executive officer) in deciding how to allocate resources and in assessing performance. Our chief executive officer allocates resources and assesses performance based upon financial information at the level. Since we operate in one operating segment, all required financial segment information is presented in the financial statements.

**Note 7 – Subsequent events**

On June 16, 2026 the Company issued an aggregate of 130,000,000 shares in connection with the conversion of loans in a total amount of $15,600.

On June 4, 2026, the Company entered into a Securities Purchase Agreement providing for the issuance of the Non-Convertible Promissory Note in the principal amount of $50,000 ($50,000 net of issuance expenses). The Non-Convertible Promissory Note carry interest of 5% and due on October 1, 2026. All payments under this Note include a 20% premium.

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the SEC and has determined that there are no other such events that warrant disclosure or recognition in the financial statements.

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

**Company Overview**

We are a pre-clinical-stage, platform technology biopharmaceutical company which has developed proprietary innovative medicines in areas of significant unmet medical needs in oncology, with a current focus on colorectal cancer ("CRC"). Our drug candidate under development for colon cancer is RCC-33, a first-in-class therapy being developed primarily in two settings: one to reduce tumor cell activity in colon cancer patients as a standalone in neoadjuvant treatment or "window of opportunity" at the time after colonoscopy, prior to cancer staging; and another for patients with refractory to therapy and adjuvant to surgery also at the time after colonoscopy. The Company hopes to start *first in human* Phase I/II clinical trials in 2027. Neoadjuvant treatment is the administration of a therapy before the surgical treatment to improve patient outcome, and our business strategy is to advance our programs through clinical studies including with partners, and to opportunistically add programs in areas of high unmet medical needs through acquisition, collaboration, or internal development.

**Results of Operations**

**<u>For the Three Months Ended May 31, 2026 and May 31, 2025</u>**

<u>Operating Expenses</u>

For the three months ended May 31, 2026, our total operating expenses were $162,763 compared to $40,380 for the three months ended May 31, 2025, resulting in an increase of $122,383. The increase is attributable to an increase in general and administrative expenses.

We incurred a financial income of $8,598 for the three months ended May 31, 2026, compared to financial loss of $19,347 for the three months ended May 31, 2025. The improvement in financial income was mainly attributable to the interest of the Company's convertible loans.

<u>Net Loss</u>

Net loss for the three months ended May 31, 2026 was $154,165 compared to net loss $59,727 for the three months ended May 31, 2025, for the reasons explained above.

**<u>For the Nine Months Ended May 31, 2026 and May 31, 2025</u>**

<u>Operating Expenses</u>

For the nine months ended May 31, 2026, our total operating expenses were $299,728 compared to $141,960 for the nine months ended May 31, 2025, resulting in an increase of $157,768. The increase is attributable to an increase in general and administrative expenses.

We incurred a financial loss of $12,254 for the nine months ended May 31, 2026, compared to $21,907 for the nine months ended May 31, 2025. The decrease in financial expenses was mainly attributable to the interest of the Company's convertible loans.

<u>Net Loss</u>

Net loss for the nine months ended May 31, 2026 was $311,982 compared to net loss $163,867 for the nine months ended May 31, 2025, for the reasons explained above.

**Liquidity and Capital Resources**

***Overview***

As of May 31, 2026, we had $9,487 in cash compared to $15,111 on August 31, 2025. We expect to incur a minimum of $1,000,000 in expenses during the next twelve months of operations. We estimate that these expenses will be comprised primarily of general expenses including overhead, legal and accounting fees, research and development expenses, and fees payable to outside medical centers for clinical studies.

**<u>Liquidity and Capital Resources during the Nine Months Ended May 31, 2026 compared to the Nine Months Ended May 31, 2025</u>**

We used cash in operations of $125,624 for the nine months ended May 31, 2026 compared to cash used in operations of $142,760 for the nine months ended May 31, 2025. The negative cash flow from operating activities for the nine months ended May 31, 2026 is primarily attributable to the Company's net loss from operations of $311,982, offset by an increase in accounts payables and accrued liabilities of $187,832 and a decrease in Accounts Receivable and pre-paid expenses of $18.

We had no cash flow from investing activities during the nine months ended May 31, 2026 and May 31, 2025.

We earned cash in financing activities of $120,000 for the nine months ended May 31, 2026 compared to $129,992 for the nine months ended May 31, 2025. The cash is from short term loan proceeds for the nine months ended May 31, 2026 and convertible loan proceeds for the nine months ended May 31, 2025.

We will have to raise funds to pay for our expenses. We may have to borrow money from shareholders, issue equity or enter into a strategic arrangement with a third party. There can be no assurance that additional capital will be available to us. We currently have no arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources. Since we have no such arrangements or plans currently in effect, our inability to raise funds for our operations will have a severe negative impact on our ability to remain a viable company.

**Going Concern**

Our independent auditors included an explanatory paragraph in their report on the accompanying unaudited financial statements regarding concerns about our ability to continue as a going concern. Our financial statements contain additional note disclosures describing the circumstances that lead to this disclosure by our independent auditors.

Our unaudited financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our unaudited financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.

There is no assurance that our operations will be profitable. Our continued existence and plans for future growth depend on our ability to obtain the additional capital necessary to operate either through the generation of revenue or the issuance of additional debt or equity.

**Off-Balance Sheet Arrangements**

We currently have no off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

**Critical Accounting Policies**

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make a number of estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. Such estimates and assumptions affect the reported amounts of revenues and expenses during the reporting period. We base our estimates on historical experiences and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions and conditions. We continue to monitor significant estimates made during the preparation of our financial statements. On an ongoing basis, we evaluate estimates and assumptions based upon historical experience and various other factors and circumstances. We believe our estimates and assumptions are reasonable in the circumstances; however, actual results may differ from these estimates under different future conditions.

See Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and Note 2, "Summary of Significant Accounting Policies" in our audited consolidated financial statements for the year ended August 31, 2025, included in our Annual Report on Form 10-K as filed on December 1<sup>st</sup>, 2025, for a discussion of our critical accounting policies and estimates.

**Item 3. Quantitative and Qualitative Disclosures About Market Risk.**

The disclosure required under this item is not required to be reported by smaller reporting companies; as such term is defined by Item 503(e) of Regulation S-K.

**Item 4. Controls and Procedures.**

***(a)***  ***Evaluation of Disclosure Controls and Procedures*** 

The Company maintains a set of disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company's management, including the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In accordance with Rule 13a-15(b) of the Exchange Act, as of the end of the period covered by this Quarterly Report on Form 10-Q, an evaluation was carried out under the supervision and with the participation of the Company's management, including its Chief Executive Officer, Chief Financial Officer and the full Audit Committee, of the effectiveness of its disclosure controls and procedures. The Audit Committee assessed, reviewed and determined that the Company's disclosure controls and procedures were effective as to this quarterly filing. Based on that evaluation, The Board accepted and ratified the findings of the Audit Committee that the Company's disclosure controls and procedures, as of May 31, 2026, the end of the period covered by this Quarterly Report on Form 10-Q, were effective to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and is accumulated and communicated to the Company's management, including the Chief Executive Officer, Chief Financial Officer, and Audit Committee as appropriate to allow timely decisions regarding required disclosure.

***(b)***  ***Changes in Internal Control over Financial Reporting*** 

There were no changes in our internal control over financial reporting during the period ending May 31, 2026, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

***(c)***  ***Limitations on the Effectiveness of Internal Controls*** 

Readers are cautioned that our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will necessarily prevent all fraud and material error. An internal control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our control have been detected. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any control design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate.

**PART II – OTHER INFORMATION**

**Item 1. Legal Proceedings.**

None.

**Item 1A. Risk Factors.**

We are a smaller reporting company as defined in Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.

**Item 2. Recent Sale of Unregistered Securities.**

None.

**Item 5. Other Information.**

During the quarter ended May 31, 2026, no director or officer of the Company adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

**Item 6. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| Exhibit 31.1\* | [Certification by the Principal Executive Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))](cnbx_ex3101.htm) |
| Exhibit 31.2\* | [Certification by the Principal Financial Officer of Registrant pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a))](cnbx_ex3102.htm) |
| Exhibit 32.1\*\* | [Certification by the Principal Executive Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](cnbx_ex3201.htm) |
| Exhibit 32.2\*\* | [Certification by the Principal Financial Officer pursuant to 18 U.S.C. 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](cnbx_ex3202.htm) |
| 101.INS\*\*\* | Inline XBRL Instance Document |
| 101.SCH\*\*\* | Inline XBRL Taxonomy Extension Schema Document |
| 101.CAL\*\*\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\*\*\* | Inline XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\*\*\* | Inline XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\*\*\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

______________________________

\* Filed herewith.

\*\* Furnished herewith.

\*\*\* XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

**SIGNATURES**

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CNBX Pharmaceuticals Inc.** | **CNBX Pharmaceuticals Inc.** |
| Date: June 24, 2026 | By: | *<u>/s/ Eyal Barad</u>* |
|  |  | Eyal Barad |
|  | Title: | Chief Executive Officer<br> (Principal Executive Officer) |
| Date: June 24, 2026 | By: | *<u>/s/ Uri Ben Or</u>* |
|  |  | Uri Ben Or |
|  | Title: | Chief Financial Officer<br> (Principal Financial Officer) |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF**

**THE SARBANES-OXLEY ACT OF 2002**

I, Eyal Barad, certify that:

1. I have reviewed this Form 10-Q of CNBX PHARMACEUTICALS INC.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: June 24, 2026 | By: | */s/ Eyal Barad* |
|  |  | Eyal Barad |
|  |  | Director, Chief Executive Officer<br> CNBX PHARMACEUTICALS INC. |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 302 OF**

**THE SARBANES-OXLEY ACT OF 2002**

I, Uri Ben Or, certify that:

1. I have reviewed this Form 10-Q of CNBX PHARMACEUTICALS INC.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: June 24, 2026 | By: | */s/ Uri Ben Or* |
|  |  | Uri Ben Or |
|  |  | Chief Financial Officer<br> CNBX PHARMACEUTICALS INC. |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION OF**

**PRINCIPAL EXECUTIVE OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF**

**THE SARBANES-OXLEY ACT OF 2002**

In connection with this Quarterly Report of CNBX PHARMACEUTICALS INC. (the "Company") on Form 10-Q for the quarter ending May 31, 2026, as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report"), I, Eyal Barad, Director and Chief Executive Officer (Principal Executive Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1. Such Quarterly Report on Form 10-Q for the quarter ending May 31, 2026, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending May 31, 2026, fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: June 24, 2026 | By: | */s/ Eyal Barad* |
|  |  | Eyal Barad |
|  |  | Director, Chief Executive Officer<br> CNBX PHARMACEUTICALS INC. |

---

## Exhibit 32.2

**Exhibit 32.2**

**CERTIFICATION OF**

**PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF**

**THE SARBANES-OXLEY ACT OF 2002**

In connection with this Quarterly Report of CNBX PHARMACEUTICALS INC. (the "Company") on Form 10-Q for the quarter ending May 31, 2026, as filed with the U.S. Securities and Exchange Commission on the date hereof (the "Report"), I, Uri Ben Or, Chief Financial Officer (Principal Financial Officer) of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

1. Such Quarterly Report on Form 10-Q for the quarter ending May 31, 2026, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in such Quarterly Report on Form 10-Q for the quarter ending May 31, 2026, fairly presents, in all material respects, the financial condition and results of operations of the Company.

---

| | | |
|:---|:---|:---|
| Date: June 24, 2026 | By: | */s/ Uri Ben Or* |
|  |  | Uri Ben Or |
|  |  | Chief Financial Officer<br> CNBX PHARMACEUTICALS INC. |

---